Date | Price Target | Rating | Analyst |
---|---|---|---|
9/9/2024 | $46.00 → $33.00 | Outperform | Leerink Partners |
12/8/2023 | $41.00 | Overweight | Wells Fargo |
5/18/2023 | $48.00 | Buy | Canaccord Genuity |
4/13/2023 | $44.00 | Outperform | Robert W. Baird |
12/14/2022 | $33.00 | Buy | Stifel |
12/7/2022 | $42.00 | Overweight | JP Morgan |
9/1/2022 | $36.00 | Buy | Citigroup |
7/20/2022 | $33.00 | Outperform | SVB Leerink |
10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)
SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced its presentations at the European Respiratory Society (ERS) International Congress 2024 taking place in Vienna, Austria September 7 - 11, 2024. "Presentations made by Pliant colleagues and investigators at the 2024 ERS Congress include additional clinical data from our recently announced type 1 collagen PET imaging study, an integrated safety summary from our INTEGRIS clinical programs and non-clinical data from our bexotegrast devel
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following September investor events. 2024 Wells Fargo Healthcare Conference Keith Cummings, M.D., Pliant's Chief Financial Officer, and Éric Lefebvre, M.D., Pliant's Chief Medical Officer, will participate in a fireside chat on Wednesday, September 4, 2024, at 1:30 p.m. Eastern Time.H.C. Wainwright 26th Annual Global Investment Conference Keith Cummings, M.D. and Éric Lefebvre, M.D., will participate in a fi
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo
Leerink Partners resumed coverage of Pliant Therapeutics with a rating of Outperform and set a new price target of $33.00 from $46.00 previously
Wells Fargo initiated coverage of Pliant Therapeutics with a rating of Overweight and set a new price target of $41.00
Canaccord Genuity initiated coverage of Pliant Therapeutics with a rating of Buy and set a new price target of $48.00
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo
Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from INTEGRIS-PSC 320 mg dose group demonstrated bexotegrast was well tolerated with continued antifibrotic and anti-cholestatic activity observed at 24 weeks across multiple measures BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and
SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Board of Directors. "Steve is a tremendous addition to our board, bringing extensive strategic leadership experience and a depth of financial expertise that will benefit Pliant's continued evolution as a late-stage clinical company," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. "Steve's broad financial experience will be highly complimentary to the strong science
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced
Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. Members of Pliant's management will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto and a principal investigator in the INTEGRIS-PSC trial. The conference call will be simultaneously webcast online and will be accessible from the Events & Presentation section of Pliant's website. The live audio of the conference call c
Needham analyst Joseph Stringer reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $38 price target.
HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.
Bexotegrast at 320 mg was well tolerated up to 40 weeks of treatment with no treatment-related severe or serious adverse events320 mg cohort demonstrated improvement in liver stiffness by transient elastography at Week 24 compared to placeboStatistically significant improvement in alkaline phosphatase (ALP) levels over 24 weeks compared to placeboContinued improvement in hepatocyte function and bile flow by contrast MRI imaging observed from Week 12 to Week 24FDA guidance provided clarity on next steps of PSC development programSOUTH SAN FRANCISCO, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced positive 24-week data from the 320 mg cohort of